Bifogade filer
2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG.
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
PreComb Therapeutics AG based in Switzerland and 2cureX AB have signed a Letter of Intent (LOI) to explore a strategic alliance that could align the scientific and commercial strengths of both companies to establish a new global benchmark in functional precision oncology.
This partnership, launched within the framework of Operation Twin Code—2cureX’s integrated growth strategy—would bring together two of Europe’s most advanced platforms in organoid-based drug response testing.
Nathaniel Hutley, Interim CEO of 2cureX AB, commented:
“These discussions have the potential to lead to more than a partnership and I believe we will eventually come together to deliver a full-stack strategy. 2cureX AB holds the exclusive license to commercialize IndiTreat® from 2cureX AS, and with PreComb’s discovery engine now potentially joining forces, we’re building an end-to-end precision platform—from pharma R&D through to patient care. PreComb leads the charge on pharma and biotech services, while 2cureX AS focuses on patient care in the clinic. Together, we cover everything from discovery to decision.”
Ole Thastrup, Chairman of 2cureX AB, added:
“By exploring this alliance with PreComb, we are setting the stage for the next chapter in oncology. Functional precision testing should be the clinical standard—not the exception. This collaboration would allow us to deliver on that vision faster, and at scale.”
Hal Bosher, CEO of PreComb Therapeutics, stated:
“PreComb is currently focused on bringing functional testing into the pharma and research ecosystem. With 2cureX AB and 2Curex AS, we will gain an experienced partner that shares our vision of scale, clinical credibility, and global reach.”